CN100413506C - 改进的药物组合物 - Google Patents

改进的药物组合物 Download PDF

Info

Publication number
CN100413506C
CN100413506C CNB971801495A CN97180149A CN100413506C CN 100413506 C CN100413506 C CN 100413506C CN B971801495 A CNB971801495 A CN B971801495A CN 97180149 A CN97180149 A CN 97180149A CN 100413506 C CN100413506 C CN 100413506C
Authority
CN
China
Prior art keywords
water
suspension
oil
compositions
ceftiofur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB971801495A
Other languages
English (en)
Chinese (zh)
Other versions
CN1238690A (zh
Inventor
T·P·福斯特
D·L·凯弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100413506(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1238690A publication Critical patent/CN1238690A/zh
Application granted granted Critical
Publication of CN100413506C publication Critical patent/CN100413506C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB971801495A 1996-12-09 1997-12-03 改进的药物组合物 Expired - Lifetime CN100413506C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 1996-12-09
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions

Publications (2)

Publication Number Publication Date
CN1238690A CN1238690A (zh) 1999-12-15
CN100413506C true CN100413506C (zh) 2008-08-27

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971801495A Expired - Lifetime CN100413506C (zh) 1996-12-09 1997-12-03 改进的药物组合物

Country Status (21)

Country Link
US (1) US5736151A (cg-RX-API-DMAC7.html)
EP (1) EP0941095B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001505910A (cg-RX-API-DMAC7.html)
KR (1) KR100544248B1 (cg-RX-API-DMAC7.html)
CN (1) CN100413506C (cg-RX-API-DMAC7.html)
AT (1) ATE264681T1 (cg-RX-API-DMAC7.html)
AU (1) AU746666B2 (cg-RX-API-DMAC7.html)
BR (1) BR9714967B1 (cg-RX-API-DMAC7.html)
CA (1) CA2269682C (cg-RX-API-DMAC7.html)
CZ (1) CZ297632B6 (cg-RX-API-DMAC7.html)
DE (1) DE69728783T2 (cg-RX-API-DMAC7.html)
DK (1) DK0941095T3 (cg-RX-API-DMAC7.html)
ES (1) ES2218705T3 (cg-RX-API-DMAC7.html)
FI (1) FI991302L (cg-RX-API-DMAC7.html)
HU (1) HUP0000564A3 (cg-RX-API-DMAC7.html)
NO (1) NO325475B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336183A (cg-RX-API-DMAC7.html)
PL (1) PL190662B1 (cg-RX-API-DMAC7.html)
PT (1) PT941095E (cg-RX-API-DMAC7.html)
SK (1) SK72399A3 (cg-RX-API-DMAC7.html)
WO (1) WO1998025621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
AU8832301A (en) * 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
EP1528926A1 (en) * 2002-08-07 2005-05-11 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
ES2270361T3 (es) * 2003-03-20 2007-04-01 Pharmacia Corporation Formulacion dispersable de un agente antiinflamatorio.
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
AU2004258746A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
PL2874624T3 (pl) 2012-07-17 2020-07-27 Bayer New Zealand Limited 3 Argus Place Hillcrest, Auckland 0627 / NZ Wstrzykiwalne formulacje antybiotykowe i sposoby ich zastosowania
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
US10420776B2 (en) 2016-10-13 2019-09-24 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL260648A (cg-RX-API-DMAC7.html) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
DE3650526T2 (de) * 1985-08-12 1996-10-31 Upjohn Co Umwandlung des cephalosporin-hydrohalid-salzes zu einem alkalimetallsalz
US5134137A (en) * 1987-11-10 1992-07-28 The Upjohn Company Cephalosporin antibiotics
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
KR920702616A (ko) * 1989-06-13 1992-10-06 원본미기재 약제를 전달하기 위한 무수 오일-기제된 액체 현탁액
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts

Also Published As

Publication number Publication date
FI991302A0 (fi) 1999-06-08
EP0941095A1 (en) 1999-09-15
CZ297632B6 (cs) 2007-02-14
CA2269682A1 (en) 1998-06-18
ATE264681T1 (de) 2004-05-15
CZ202599A3 (cs) 1999-09-15
AU746666B2 (en) 2002-05-02
ES2218705T3 (es) 2004-11-16
EP0941095B1 (en) 2004-04-21
HK1023292A1 (zh) 2000-09-08
BR9714967A (pt) 2001-10-30
BR9714967B1 (pt) 2010-06-29
DE69728783T2 (de) 2005-03-31
NO992780D0 (no) 1999-06-08
NO325475B1 (no) 2008-05-13
JP2001505910A (ja) 2001-05-08
AU5452998A (en) 1998-07-03
KR20000069360A (ko) 2000-11-25
SK72399A3 (en) 2000-05-16
FI991302A7 (fi) 1999-06-08
KR100544248B1 (ko) 2006-01-23
NO992780L (no) 1999-06-08
US5736151A (en) 1998-04-07
WO1998025621A1 (en) 1998-06-18
DE69728783D1 (de) 2004-05-27
CN1238690A (zh) 1999-12-15
PT941095E (pt) 2004-08-31
HUP0000564A3 (en) 2001-01-29
DK0941095T3 (da) 2004-08-02
CA2269682C (en) 2009-04-14
NZ336183A (en) 2000-12-22
PL190662B1 (pl) 2005-12-30
FI991302L (fi) 1999-06-08
HUP0000564A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
US5736151A (en) Antibiotic oil suspensions
CN1087933C (zh) 装胶囊的药物
CN104244983A (zh) 控制释放组合物及其使用方法
AU2012359296B2 (en) Antibiotic formulations
WO2004014390A1 (en) Novel pharmaceutical composition of ceftiofur
HK1023292B (en) Improved pharmaceutical compositions
US12295958B2 (en) Ready-to-use injectable formulations
RU2777360C1 (ru) Готовые к применению лекарственные формы для инъекций
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms
AU2024278169A1 (en) Controlled Release Compositions and their Methods of Use
AU2002328168B2 (en) Novel pharmaceutical composition of ceftiofur
JPH10279478A (ja) シスプラチンカプセル剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1023292

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: PAH

Free format text: FORMER OWNER: UPJOHN CO.

Effective date: 20130619

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: ZOETIS PU CO., LTD.

Free format text: FORMER NAME: PAH

CP01 Change in the name or title of a patent holder

Address after: American New Jersey

Patentee after: Zoetis Services LLC

Address before: American New Jersey

Patentee before: PAHPU LLC

Address after: Michigan

Patentee after: PHARMACIA & UPJOHN CO.,LLC

Address before: Michigan

Patentee before: PHARMACIA & UPJOHN Co.

TR01 Transfer of patent right

Effective date of registration: 20130619

Address after: American New Jersey

Patentee after: PAHPU LLC

Address before: Michigan

Patentee before: PHARMACIA & UPJOHN CO.,LLC

ASS Succession or assignment of patent right

Owner name: SHUOTENG SERVICE LLC

Free format text: FORMER OWNER: ZOETIS PU CO., LTD.

Effective date: 20150730

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150730

Address after: New jersey, USA

Patentee after: Zoetis Services LLC

Address before: American New Jersey

Patentee before: Zoetis Services LLC

CX01 Expiry of patent term

Granted publication date: 20080827

CX01 Expiry of patent term